Tert-butyl 2-[4-[9-(4-iodophenyl)-6-[4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]piperazin-1-ium-1-ylidene]xanthen-3-yl]piperazin-1-yl]acetate;chloride | 1079889-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: Tert-butyl 2-[4-[9-(4-iodophenyl)-6-[4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]piperazin-1-ium-1-ylidene]xanthen-3-yl]piperazin-1-yl]acetate;chloride
• CAS: 1079889-29-4
• 化学式: C₃₉H₄₈IN₄O₅*Cl
• 分子量: 815.191
• InChiKey: YMNFIMSWAWQZOT-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.71
• 重原子数：
  50
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  74.6
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  溴乙酸叔丁酯 、 Tert-butyl 4-[9-(4-iodophenyl)-6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-ium-1-ylidene]xanthen-3-yl]piperazine-1-carboxylate;chloride 在 三氟乙酸 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以76%的产率得到Tert-butyl 2-[4-[9-(4-iodophenyl)-6-[4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]piperazin-1-ium-1-ylidene]xanthen-3-yl]piperazin-1-yl]acetate;chloride
  参考文献：
  名称：

  具有环胺取代基的罗莎胺的合成和光谱性质。

  摘要：

  rosamines A和若丹明B之间存在紧密的结构相似性，但rosamine类中的各种结构及其光谱特性尚未深入研究。该手稿描述了一种简明的，可扩展的溶液相方法，可得到包括一些水溶性衍生物的罗莎明1-5和12-15。在一个测试案例（针对15个案例）中，还形成了一个示例性的蛋白质偶联物。在整个过程中，这些产物被分离和纯化，并且发现合成是可扩展的。此外，具有这些环胺取代基的罗莎胺显示出溶剂依赖性的荧光强度，并且在氯化烃中具有高的量子产率。在某些情况下，环胺取代基的性质显示出以pH依赖的方式调节母体分子的荧光。这些胺取代基的环大小也与其某些光谱性质相关。由一些加成产物1-5制备了几种水溶性的罗萨明，其中的15个之一通过酰胺键与抗生物素蛋白有效地缀合。15和15-亲和素在水性介质中的光谱性质非常相似。

  DOI：

  10.1021/jo800902j

文献信息

• [EN] ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE ROSAMINE COMME AGENTS POUR LE TRAITEMENT D'UN CANCER
  申请人：CANCER RES INITIATIVES FOUNDAT

  公开号：WO2010033011A1

  公开（公告）日：2010-03-25

  The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R1 represents aryl, Het1 or C1-6 alkyl, which latter group is optionally substituted by aryl or Het2; R2a and R2b together form C3.8n-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O-C1-4, alkyl.and which alkylene group is optionally interrupted by X1; R3a and R3b together form C3-6 /7-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O-C1-4 alkyl, and which alkylene group is optionally interrupted by X2; X1 and X2 independently represent O, S, or NR4; R4 represents, independently at each occurrence, H, C(O)OR5, C(0)R6a, C(O)N(R6b)R6c or C1-6, alkyl, which latter group is optionally substituted by one or more substituents selected from halo, aryl and Het3 or is substituted by a single C(0)0R1a group; R4a represents H or C1-4 alkyl; R5 represents aryl, Het4 or C1-6 alkyl optionally substituted by one or more substituents selected from halo, aryl and Het5; R5e to R6d independently represent H or R5; each aryl independently represents a C6-10 carbocyclic aromatic group, which group may comprise either one or two rings and may be substituted by one or more substituents selected from halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR7, phenyl, naphthyl and Het6) and OR8; R7 and R8 independently represent H, C1-4 alkyl (optionally substituted by one or more halo groups or by a single phenyl or C(O)OR8a substituent), Het7, phenyl or naphthyl; R8a represents H or C1-4 alkyl; Het1 to Het7 independently represent 5- to 10-membered aromatic, fully saturated or partially unsaturated heterocyclic groups containing one or.more heteroatoms selected from oxygen, nitrogen and/or sulfur, which heterocyclic groups may comprise one or two rings and may be substituted by one or more substituents selected from Halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR9 and phenyl) and OR10; R9 and R10 independently represent H, C1-4 alkyl or phenyl; unless otherwise specified, alkyl groups are optionally substituted by one or more halo atoms; and A' represents a pharmaceutically acceptable anion. Also disclosed are methods for making and using ' compounds as well as pharmaceutical compositions.

  本发明涉及一类新的罗萨明衍生物，其中在一个实施例中，化合物具有结构（I）或其任何药学上可接受的盐或溶剂，其中：R1代表芳基、Het1或C1-6烷基，后者可由芳基或Het2取代；R2a和R2b一起形成C3.8n-烷基，该烷基可由卤素、C1-4烷基、C(O)OH和C(O)O-C1-4烷基中选择的一个或多个取代基取代，并且该烷基可由X1中断；R3a和R3b一起形成C3-6/7-烷基，该烷基可由卤素、C1-4烷基、C(O)OH和C(O)O-C1-4烷基中选择的一个或多个取代基取代，并且该烷基可由X2中断；X1和X2独立地表示O、S或NR4；R4在每次出现时独立地表示H、C(O)OR5、C(0)R6a、C(O)N(R6b)R6c或C1-6烷基，后者可由卤素、芳基和Het3中选择的一个或多个取代基取代，或者由单个C(0)0R1a基团取代；R4a表示H或C1-4烷基；R5代表芳基、Het4或C1-6烷基，可由卤素、芳基和Het5中选择的一个或多个取代基取代；R5e到R6d独立地表示H或R5；每个芳基独立地表示一个含有6-10个碳环芳族的芳基，该芳基可能包含一个或两个环，并且可能被一个或多个取代基如卤素、CN、C1-6烷基（后者可由一个或多个取代基如卤素、OR7、苯基、萘基和Het6取代）和OR8取代；R7和R8独立地表示H、C1-4烷基（可由一个或多个卤素基或单个苯基或C(O)OR8a取代基取代）、Het7、苯基或萘基；R8a表示H或C1-4烷基；Het1到Het7独立地表示含有一个或多个异氧、氮和/或硫的芳族、完全饱和或部分不饱和的杂环基，这些杂环基可能包含一个或两个环，并且可能被一个或多个取代基如卤素、CN、C1-6烷基（后者可由一个或多个取代基如卤素、OR9和苯基取代）和OR10取代；R9和R10独立地表示H、C1-4烷基或苯基；除非另有规定，烷基可能由一个或多个卤素原子取代；A'表示药学上可接受的阴离子。还公开了制备和使用该化合物以及制药组合物的方法。